178 related articles for article (PubMed ID: 20211249)
1. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.
Samuni Y; Ishii H; Hyodo F; Samuni U; Krishna MC; Goldstein S; Mitchell JB
Free Radic Biol Med; 2010 Jun; 48(11):1559-63. PubMed ID: 20211249
[TBL] [Abstract][Full Text] [Related]
2. Redox properties and thiol reactivity of geldanamycin and its analogues in aqueous solutions.
Samuni A; Goldstein S
J Phys Chem B; 2012 Jun; 116(22):6404-10. PubMed ID: 22591491
[TBL] [Abstract][Full Text] [Related]
3. One-electron reduction of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: a pulse radiolysis study.
Goldstein S
J Phys Chem A; 2011 Aug; 115(32):8928-32. PubMed ID: 21718076
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis.
Madrigal-Matute J; Fernandez-Garcia CE; Gomez-Guerrero C; Lopez-Franco O; Muñoz-Garcia B; Egido J; Blanco-Colio LM; Martin-Ventura JL
Cardiovasc Res; 2012 Jul; 95(1):116-23. PubMed ID: 22547655
[TBL] [Abstract][Full Text] [Related]
5. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.
Fukuyo Y; Inoue M; Nakajima T; Higashikubo R; Horikoshi NT; Hunt C; Usheva A; Freeman ML; Horikoshi N
Cancer Res; 2008 Aug; 68(15):6324-30. PubMed ID: 18676857
[TBL] [Abstract][Full Text] [Related]
7. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
8. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
9. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
[TBL] [Abstract][Full Text] [Related]
11. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
[TBL] [Abstract][Full Text] [Related]
12. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Rao R; Lee P; Fiskus W; Yang Y; Joshi R; Wang Y; Buckley K; Balusu R; Chen J; Koul S; Joshi A; Upadhyay S; Tao J; Sotomayor E; Bhalla KN
Cancer Biol Ther; 2009 Jul; 8(13):1273-80. PubMed ID: 19440035
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
16. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
Seaton A; Maxwell PJ; Hill A; Gallagher R; Pettigrew J; Wilson RH; Waugh DJ
Br J Cancer; 2009 Nov; 101(9):1620-9. PubMed ID: 19809428
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
Guo W; Reigan P; Siegel D; Ross D
Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
[TBL] [Abstract][Full Text] [Related]
20. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.
Mahanta S; Pilla S; Paul S
Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
